The Medicines Co.'s ongoing quest to narrow its focus, free up cash and reduce burn in the face of multiple challenges headlined its third quarter earnings announcement. By year's end, the Parsippany, N.J.-based company said that it expects to announce a transaction to sell its infectious disease business, to slash its workforce to fewer than 60 staff, and to start all trials in the LDL-C lowering program for inclisiran, a protein convertase subtilisin/kexin type 9 (PCSK9) candidate it expects to file with the FDA by the end of 2019.